Next-generation molecular diagnostics company BillionToOne Inc (Nasdaq:BLLN) announced on Tuesday the release of Northstar PGx and Northstar Select CH as add-on applications for Northstar Select, its therapy selection liquid biopsy for advanced solid tumours.

This launch expands the Northstar platform beyond genomic profiling to address chemotherapy safety and clonal hematapoeisis -- two critical decision points in selecting the right therapy for patients.

Northstar PGx provides pharmacogenomic insight into key variants in DPYD and UGT1A1, genes recognized in oncology guidelines and FDA labeling for their impact on fluoropyrimidine- (5-FU) and irinotecan-based therapies. By integrating pharmacogenomic context directly into the liquid biopsy workflow with the same 5-day average turnaround-time, Northstar PGx aims to support more informed discussions around dosing, monitoring, and treatment planning, without delaying care.

Northstar Select CH addresses clonal hematopoiesis (CH), a common source of biological false positives in cfDNA testing. Accurately identifying the origin of alterations found circulating in the blood can optimize treatment confidence and avoid exposing patients to unnecessary toxicity and ineffective treatments.